Leflunomide for cytomegalovirus: bench to bedside

Area of Science:

• Immunology
• Virology
• Pharmacology

Background:

• Cytomegalovirus (CMV) is a significant threat to transplant recipients, causing morbidity and mortality.
• Balancing graft preservation and CMV disease control is a clinical challenge.
• Current CMV treatments primarily target viral DNA synthesis.

Purpose of the Study:

• To review the accumulated knowledge on leflunomide's role in managing CMV infections over the past decade.
• To assess leflunomide's potential as an antiviral and immunosuppressive agent in transplantation.
• To highlight leflunomide's unique mechanism of action against CMV.

Main Methods:

• Review of existing literature on leflunomide and CMV.
• Analysis of experimental allograft models demonstrating immunosuppressive activity.
• Evaluation of in vitro and in vivo antiviral data against CMV.
• Assessment of leflunomide's pharmacokinetic properties, including oral bioavailability.

Main Results:

• Leflunomide exhibits immunosuppressive activity relevant to allograft models.
• The drug demonstrates antiviral effects against CMV in vitro and in vivo.
• Leflunomide inhibits CMV virion assembly, a distinct mechanism from current antivirals.
• Evidence suggests activity against both ganciclovir-sensitive and -resistant CMV strains.
• Leflunomide possesses good oral bioavailability and is economical, particularly for resource-poor settings.

Conclusions:

• Leflunomide presents a dual action: immunosuppression for graft preservation and antiviral activity against CMV.
• Its unique mechanism and favorable characteristics make it a potentially valuable therapeutic option for transplant recipients.
• Further structured clinical trials are warranted to confirm leflunomide's efficacy and safety in CMV management and chronic rejection prevention.